ID
26749
Description
Study Part: Brief Physical Examination Week 5 PK Visit (Visit 9). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165
Keywords
Versions (1)
- 10/23/17 10/23/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
October 23, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Brief Physical Examination Week 5 PK Visit (Visit 9) Ropinirole Parkinson Disease 101468/165
Brief Physical Examination Week 5 PK Visit (Visit 9)
- StudyEvent: ODM
Similar models
Brief Physical Examination Week 5 PK Visit (Visit 9)
- StudyEvent: ODM
C0019994 (UMLS CUI [1,2])